Dernièrement…

Uncategorized


2 May 2024

Amoéba’s Board of Directors renewed to support the company’s new strategic ambitions

Amoéba, an industrial biotech specialised in the treatment of microbiological risk, developing a biocontrol agent for the protection of plants in agriculture and a range of anti-ageing cosmetic ingredients, is appointing a new Board of Directors, welcoming four well-known figures specialised in the fields that represent the company’s core activities.


15 February 2024

AMOEBA: Additional information and areas for growth

Amoéba announces additional information following a change in governance, and a review of the company’s growth focus.


5 February 2024

AMOEBA: Corporate governance change and review of the company’s growth strategy

Amoéba announces additional information following a change in governance, and a review of the company’s growth focus.


15 December 2023

AMOEBA: Commercial strategy and governance further strengthened and industrial project deferred 

Amoéba today announced a strengthening of governance and commercial strategy and the deferral of the industrial project


23 November 2023

AMOEBA : A year of field trials that confirms AXPERA’s strategic positioning

Amoéba announces the publication of its 2023 test results, a campaign year that allows the refining of AXPERA’s commercial strategy.


18 October 2023

AMOEBA : Publication of a new scientific paper in Plants

Amoéba announces the publication of a third peer-reviewed scientific article in Plants, presenting the efficacy of Amoéba’s biocontrol products on tomato late blight and powdery mildews of tomato.


16 October 2023

AMOEBA : Convincing results for the use of amoeba lysate in cosmetics.

Amoéba announces that it has obtained convincing results for the use of Willaertia magna C2c Maky lysate in cosmetic skin care and has filed a patent application for this invention.


12 October 2023

AMOEBA announces the beginning of construction of its USIBIAM biocontrol plant in Cavaillon

Amoéba announces the start of work on the USIBIAM industrial project in Cavaillon on schedule.


5 October 2023

Amoéba: first half-year reporting 

Amoéba announces reporting its earnings for the first half of 2023


13 July 2023

Regulatory timetable for Europe’s biocontrol application on track

Amoéba confirms that the regulatory timetable for the biocontrol active substance application is in line with the Company’s forecasts.


5 June 2023

AMOEBA introduces its AXPERA brand for the biocontrol application

Amoéba announces today the brand name of its biocontrol solutions, with a view to commercialization expected in early 2025.


20 April 2023

Initiation of coverage by Portzamparc

Amoéba announces today that Portzamparc – BNP Paribas Group has initiated coverage on the company.


19 April 2023

Ordinary and extraordinary general meeting to be help on 25 May 2023

Amoéba informs that the notice of the meeting as a notice of convocation, including the agenda and the planned resolutions, was published in the BALO (Bulletin of obligatory legal announcements) of 19 april, 2023.


18 April 2023

AMOEBA : Availability of the 2022 Universal Registration Document

Amoéba announces that the 2022 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers-AMF) on April 18, 2023


31 March 2023

Amoéba announces its collaboration with Nissan Chemical Corporation

Amoéba announces that Nissan Chemical Corporation has started a performance evaluation study of the mixture of one of its products with an Amoéba biocontrol experimental product.


30 March 2023

Amoéba : 2022 results 

Amoéba today announces its annual results for the year ending 31 December 2022.


29 March 2023

Amoéba obtains €5.9 million in funding from BPI France as part of France 2030 program

Amoéba announces the support of BPI France in the framework of the national financing plan “France 2030”.


13 March 2023

Initiation report from the analyst Edison Group

Amoéba announces that Edison Group, a London-based equity research house, has initiated coverage on the company.


16 February 2023

Submission of the building permit application for the 100% biocontrol manufacturing unit

Amoéba announces that it has applied for building permit for its new production site dedicated to biocontrol application, based in Cavaillon in the south of France.


15 February 2023

Signature of a new financing agreement with Nice & Green

Amoéba announces the signature of a new simple bond financing agreement of 9 million euros with the Swiss company Nice & Green SA.


27 January 2023

Cancellation of the issue of the 8th optional tranche of OCAs and signature of a support contract with Redbridge Debt and Treasury Advisory

Amoéba announces that it has terminated its convertible bond issue contract with Nice & Green SA and waived the issue of the 8th optional tranche of 80 OCAs. In order to adapt its financial strategy to its new industrial transformation challenges, Amoéba has concluded a contract with Redbridge Debt and Treasury Advisory to assist it in its search for financing.

 


20 December 2022

US EPA approves Amoeba’s biocide in the US

Amoéba informs that the US Environmental Protection Agency (US EPA) has approved the use of the Willaertia magna C2c Maky as an active substance for use cooling systems.


14 December 2022

Issuance of the seventh tranche of 40 bonds convertible into shares

AMOEBA announces the issuance of the seventh tranche of 40 bonds convertible into shares as part of its new bond financing with incentive program with Nice & Green S.A.


3 November 2022

US EPA approves Amoeba’s biocontrol solution in the US

Amoéba announces that the US EPA has approved the use of the lysate of Willaertia magna C2c Maky as an active substance for use in plant protection.


20 October 2022

Publication of 2022 field trial results

Amoéba announces the publication of its 2022 field trial results, a record year for the number and performance of field trials.


19 October 2022

Amoeba withdraws its biocide file in Canada

Amoéba announces that it will not pursue the application for its living amoeba-based biocide in Canada.


18 October 2022

Publication of a new scientific article in Plants

Amoéba announces the publication of a scientific article concerning the efficacy of its biocontrol products to fight potato late blight.


12 October 2022

US EPA approves tolerance exemption for the biocontrol active substance on foodstuffs

Amoéba informs that the US EPA approves tolerance exemption for the biocontrol active substance on foodstuffs.

 


3 October 2022

2022 Interim Financial Report

Amoéba announces today that it has published its Interim Financial Report for 2022.


29 September 2022

Amoeba announces its half-year results for 2022

Amoeba announces its half-year results for 2022


29 September 2022

US EPA about to approve Amoeba’s biocontrol solution for use in agriculture

Amoéba informs that the United States Environmental Protection Agency (US EPA) has made a positive pre-decisional determination following its assessment of the application dossier for the use of the Lysate of Willaertia magna C2c Maky as a biocontrol active ingredient (biopesticide) in agriculture.


15 September 2022

AMOEBA : insuance of the sixth tranche of 60 bonds convertible into shares

Amoéba announces the issuance of the sixth tranche of 60 bonds convertible into shares.


10 August 2022

US EPA about to approve Amoéba’s biocide for use in closed cooling systems

Amoéba informs that the US EPA has made a positive pre-decisional determination for the use of Amoéba’s biocide in closed cooling systems.


13 June 2022

Amoéba : Issuance of the 5th tranche of OCA

Amoéba announces the issuance of the fifth tranche of 60 bonds convertible into shares as part of its new bond financing with incentive program with Nice & Green S.A.


30 May 2022

Amoéba: US regulatory calendar update

Amoeba announces that the US EPA, in charge of the evaluation of the biocide and biocontrol applications in the United States, has requested an extension of the assessment period : the conclusions should now be available in the second half of 2022.


6 May 2022

Ordinary and extraordinary general meeting to be held on 24 May 2022

Amoéba announces the availability of preparatory documents for the General Assembly of May 24, 2022


3 May 2022

Amoeba: Malta recommends the non-approval of the “biocide” active substance for the European territory

Amoeba announces that the Maltese authority recommends the non-approval of the biocidal active substance for the European territory


25 April 2022

Amoéba: Austria recommends the approval of the biocontrol application in Europe

Amoéba announces that AGES, in charge of the application for approval of the biocontrol active substance “Lysate of Willaertia magna C2c Maky”, recommends its approval for use in plant protection on the European territory.


13 April 2022

Amoéba : Publication of the 2021 Universal Registration Document

Amoéba announces that the 2021 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers AMF) on April 12, 2022.


5 April 2022

Amoéba : Deferral of the 5th tranche of OCAs

Amoéba announces having exercised the suspension option relating to the issuance of the 5th tranche of OCAs, initially scheduled for April 5, 2022.


25 March 2022

Update of the European regulatory application calendar

Amoéba announces a report of the conclusion of the evaluation of the European biocide and biocontrol dossiers.


24 August 2021

Results of the 2nd cereal trial campaign

Amoeba confirms its biocontrol’s effectiveness against major cereal diseases


29 July 2021

Promising results of the Biocontrol-Grapewine application

Amoéba announces the results of the field trials 3rd campaign on grapes


5 July 2021

Postponement of the biocide active substance dossier

Malta commits to finalize the report in the 4th quarter of 2021


24 June 2021

Appointment of Philippe Dujardin to the Board of Directors

Philippe Dujardin replaces Pascal Reber as independent director


2 June 2021

General Meeting of June 24, 2021

Availability of the preparatory documents for the General meeting of 27 may 2021


27 May 2021

General Meeting second convocation

Due to a lack of quorum, the General Meeting is postponed to June 24, 2021


10 May 2021

General Assembly of May 27, 2021

Amoéba provides shareholders with preparatory documents


6 April 2021

Submission of the biocide application in the USA

Amoéba has submitted the application for approval of the biocidal active substance


6 April 2021

Massive new field trials campaign

Amoeba continues testing its biocontrol product in 2021


26 March 2021

Amoéba announces the 2020 financial year results

marked by the continued development of its biocidal and biocontrol applications


12 March 2021

Research partnership with the US group GOWAN COMPANY

Amoéba extends to the U.S.A. the testing of its biocontrol


10 March 2021

Appointment of Pierre Morgon to the Board of Directors

Amoéba has appointed Pierre Morgon as censor.


10 March 2021

Development and commercialization agreement

Signature of a Letter of Intent (LOI) with PHILAGRO France


18 December 2020

Signature of a non-exclusive development and marketing agreement

in Switzerland with Stähler for its vine Bioncontrol product.